Immunology and Microbiology
Circumsporozoite Protein
100%
Plasmodium falciparum
86%
Monospecific Antibody
74%
Sporozoite
65%
Vaccine Efficacy
61%
Monoclonal Antibody
55%
Mouse
41%
RTS,S
40%
Epitope
39%
Human Monoclonal Antibody
30%
Immune Response
25%
Vaccination Policy
22%
Antibody Response
20%
Plasmodium
19%
Plasmodium berghei
16%
Toxoplasma gondii
14%
Malaria Control
13%
Toxoplasmosis
12%
Amastigote
12%
Hemozoin
12%
Amino Terminal Sequence
12%
Carboxy Terminal Sequence
10%
Immunoglobulin A
9%
Virus-Like Particle
9%
Immunoglobulin G2
8%
Mouse Model
8%
Light Chain
8%
Chagas Disease
8%
Developmental Stage
8%
T-Helper Cell
7%
Trypanosoma Cruzi
7%
CD4
7%
Human Immunoglobulin
7%
Crystal Structure
7%
Cytokine
7%
Antimalarial Agent
7%
T Cell
6%
Cross-Reactivity
6%
Antigen
6%
CD25
6%
Regulatory T Cell
6%
Virus Like Particle Vaccine
6%
Bagg Albino Mouse
6%
Protein Structure
6%
Autophagy
6%
Antibody Affinity
6%
Parasitemia
6%
Ookinete
6%
Adeno Associated Virus
6%
Alphavirus
6%
Keyphrases
Sporozoite
52%
Circumsporozoite Protein
49%
PfCSP
44%
Monoclonal Antibody
44%
Malaria
35%
Plasmodium Falciparum
30%
Epitope
22%
Liver
17%
Plasmodium Berghei
17%
Immune Protection
15%
Antibody Targeting
14%
Challenge Model
13%
Repeat Region
12%
Hemozoin
12%
Antibody Response
12%
Vaccination
12%
Protein Repeats
12%
Malaria Vaccine
11%
Pre-erythrocytic Stages
11%
Liver Stage
10%
Malaria Infection
9%
In Vivo Model
9%
In Vivo Protection
9%
Stage Development
8%
Toxoplasma Gondii (T. gondii)
7%
In Vivo Challenge
7%
Parasitemia
7%
Vaccine Antibodies
7%
IFN Production
7%
AS01
7%
High Affinity
7%
Plasmodium Liver Stage
6%
Innate Immune Response
6%
N-terminal Domain
6%
Intravenous Inoculation
6%
Inoculation Site
6%
Clinical Features
6%
Autophagy
6%
Immunoglobulin Repertoire
6%
Wortmannin
6%
Inhibitory Activity
6%
CelTOS
6%
3D Substrate
6%
Antibody-mediated Protection
6%
Vaccine Target
6%
Plasmodium Sporozoites
6%
Balb C Mice
6%
Amastigote
6%
Vulnerability
6%
Human Saliva
6%
